Advancing the management of MDS and AML: Novel immune-based approaches episode artwork

EPISODE · Sep 12, 2022 · 47 MIN

Advancing the management of MDS and AML: Novel immune-based approaches

from touchPODCAST · host touchpodcast

touchEXPERT OPINIONS for touchONCOLOGY  Listen to three experts describe the role of immune dysregulation in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML), and summarize the rationale and available data for emerging immune-based therapeutic strategies. In a short panel discussion, they consider the possible impact these therapies may have on future clinical practice. The experts Prof. Dr. med. Uwe Platzbecker — University Hospital Leipzig, Leipzig, Germany Prof. Agnieszka Wierzbowska — Medical University of Łódź, Copernicus Memorial Hospital, Łódź, Poland Prof. Valeria Santini — University of Florence, Florence, Italy This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME. For further information visit our website: touchONCOLOGY

Episode metadata supplied by the publisher feed · Published Sep 12, 2022

Embed this episode

Ready to play

Advancing the management of MDS and AML: Novel immune-based approaches

0:00 47:42

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of touchPODCAST?

This episode is 47 minutes long.

When was this touchPODCAST episode published?

This episode was published on September 12, 2022.

Can I download this touchPODCAST episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!